

April 20, 2023

Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Subject: Initial Disclosure regarding Large Corporates

Reference: SEBI Circular No. SEBI/HO/DDHS/P/CIR/P/2018/144 dated November 26, 2018

Dear Sir/Madam,

With reference to the above SEBI Circular dated November 26, 2018 in respect of fund raising by issuance of debt securities by Large Corporates (LC) disclosures and compliances thereof by such large corporates (LC), we hereby submit that Orchid Pharma Limited ("the Company") does not does not fulfil the applicability criteria of "Large Corporate" given under para 2.2 of SEBI Circular. Therefore, the Company not identified as Large Corporate under the said SEBI Circular. Copy of Annexure A is enclosed herewith.

Kindly take the above on your records.

For Orchid Pharma Limited

Marina

Marina Peter

Company Secretary & Compliance Officer



Annexure A

Format of Initial Disclosure/Annual disclosure to be made by the Company identified as a Large Corporate

Sr. No.	Particulars	Details
1	Name of Company	Orchid Pharma limited
2	CIN	L24222TN1992PLC022994
3	Outstanding borrowing of the Company as on March 31, 2023 (Rs. in crore)	143.20
4	Highest Credit Rating during the previous financial year 2022-23 along with the name of the Credit Rating Agency	CARE Ratings Limited Long Term Bank Facilities – CARE BBB; Stable And CARE BBB; Stable/CARE A3+
5	Name of the Stock Exchange in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	BSE Limited

We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 - No

Marina

Marina Peter
Company Secretary and Compliance Officer
cs@orchidpharma.com



S. K. Gupta

Sunil Kumar Gupta
Chief Financial Officer
sunilgupta@orchidpharma.com



Date: 20-04-2023

#-In terms of para 3.2(ii) of the circular, beginning F.Y 2023, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.